STOCK TITAN

Sensus Healthcare Inc - SRTS STOCK NEWS

Welcome to our dedicated page for Sensus Healthcare news (Ticker: SRTS), a resource for investors and traders seeking the latest updates and insights on Sensus Healthcare stock.

Sensus Healthcare, Inc. (Nasdaq: SRTS) is a leading medical device company dedicated to providing non-invasive and cost-effective treatments for non-melanoma skin cancer and keloids. Utilizing a proprietary low-energy x-ray radiation technology known as Superficial Radiation Therapy (SRT), Sensus Healthcare has made significant advancements in the field over more than a decade of dedicated research and development. The company’s flagship products, the SRT-100™ and SRT-100 Vision™, effectively and safely treat a variety of oncological and non-oncological skin conditions, including basal cell and squamous cell skin cancers, as well as keloids.

Based in Boca Raton, Florida, Sensus Healthcare focuses on creating innovative, minimally-invasive solutions that address critical medical needs. The company has recently announced a multi-faceted collaboration with CureRays, a radiation oncology specialist organization headquartered in Atlanta and Grass Valley, California. This partnership aims to enhance the reach and efficacy of Sensus's SRT technology, further solidifying its position as a leader in the non-invasive treatment market.

Sensus Healthcare generates the majority of its revenue from customers within the United States, offering products and services that meet the highest standards of safety and effectiveness. The company’s proprietary technology has been incorporated into its diverse portfolio, which includes the SRT-100™, SRT-100 Vision™, and a comprehensive Sentinel service program that ensures optimal device performance and customer satisfaction.

Investors and stakeholders are encouraged to stay informed about Sensus Healthcare’s latest developments. Recently, the company announced it would hold a conference call on May 9, 2024, to discuss the financial results for the first quarter of 2024 and provide updates on recent and upcoming milestones. This call will offer an in-depth overview of the company’s financial health and strategic initiatives.

For more detailed information about Sensus Healthcare, its innovative technology, products, and recent news, please visit Sensus Healthcare’s official website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.33%
Tags
buyback
-
Rhea-AI Summary
Sensus Healthcare announces Q2 2023 financial results with revenues of $4.5 million, a 33% increase from Q1 2023. Net loss for Q2 2023 was $0.4 million, compared to net income of $3.5 million in Q2 2022. Expects to ship at least 60 SRT units during 2023 and return to profitability in H2 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.97%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.8%
Tags
partnership
-
Rhea-AI Summary
Sensus Healthcare to participate in Maxim Group Virtual Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.71%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.96%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-44.38%
Tags
-
Rhea-AI Summary

On April 25, 2023, Sensus Healthcare, Inc. (SRTS) announced a conference call scheduled for May 3, 2023, at 4:30 PM ET to discuss first-quarter 2023 financial results. During this call, management will also provide a business update and discuss ongoing and upcoming milestones. Participants can pre-register for the call to receive a unique dial-in number, allowing them to bypass the operator. The live webcast will be accessible through the company’s website, with a replay available until June 3, 2023. Sensus Healthcare specializes in non-invasive treatments for oncological and non-oncological conditions, offering innovative devices for skin cancer and aesthetic procedures.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.65%
Tags
conferences earnings
Rhea-AI Summary

Sensus Healthcare (Nasdaq:SRTS) has launched Sensus Cloud, a groundbreaking cloud-based platform designed for asset and EMR management in healthcare. This platform allows healthcare providers to collect real-time data from medical devices, streamlining patient monitoring and treatment management.

Key features include an intuitive interface for tracking patient treatment history, device usage, and service details, alongside predictive analytics for proactive care management. The system ensures data security with multi-factor authentication and encryption, enhancing user and patient data protection. Sensus Healthcare will showcase this innovative platform at the American Academy of Dermatology Annual Meeting from March 17-19, 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
none

FAQ

What is the current stock price of Sensus Healthcare (SRTS)?

The current stock price of Sensus Healthcare (SRTS) is $5.38 as of February 21, 2025.

What is the market cap of Sensus Healthcare (SRTS)?

The market cap of Sensus Healthcare (SRTS) is approximately 91.7M.

What is Sensus Healthcare, Inc.?

Sensus Healthcare, Inc. is a medical device company specializing in non-invasive treatments for non-melanoma skin cancer and keloids, utilizing proprietary Superficial Radiation Therapy (SRT) technology.

What products does Sensus Healthcare offer?

Sensus Healthcare offers the SRT-100™ and SRT-100 Vision™, which are devices designed to treat oncological and non-oncological skin conditions.

What is Superficial Radiation Therapy (SRT)?

Superficial Radiation Therapy (SRT) is a low-energy x-ray radiation technology used by Sensus Healthcare to treat conditions like non-melanoma skin cancer and keloids effectively and safely.

Where is Sensus Healthcare based?

Sensus Healthcare is based in Boca Raton, Florida.

What recent collaborations has Sensus Healthcare announced?

Sensus Healthcare recently announced a collaboration with CureRays, a radiation oncology specialist organization based in Atlanta and Grass Valley, California.

How does Sensus Healthcare generate its revenue?

Sensus Healthcare generates the majority of its revenue from customers in the United States through the sale of its medical devices and services.

What is the Sentinel service program?

The Sentinel service program is a comprehensive service offered by Sensus Healthcare to ensure optimal device performance and customer satisfaction.

When is the next conference call for Sensus Healthcare?

Sensus Healthcare will hold a conference call on May 9, 2024, to discuss the financial results for the first quarter of 2024 and provide updates on recent and upcoming milestones.

Where can I find more information about Sensus Healthcare?

More information about Sensus Healthcare can be found on their official website at www.sensushealthcare.com.

What conditions can Sensus Healthcare’s devices treat?

Sensus Healthcare’s devices can treat oncological skin conditions like basal cell and squamous cell skin cancers, as well as non-oncological conditions such as keloids.
Sensus Healthcare Inc

Nasdaq:SRTS

SRTS Rankings

SRTS Stock Data

91.71M
13.57M
19.01%
24.27%
3.27%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
BOCA RATON